According to the firm's 10-K filing dated 3/16/2001, in February 1999, the Oran case was dismissed with prejudice by the U.S. District Court for the District of New Jersey. In September 2000, that dismissal was affirmed by the United States Court of Appeals for the Third Circuit and the case has now been closed.

The original Complaint alleges that during the Class Period, AHP and certain of its directors and officers violated Sections 10 (b) and 20 (a) of the Securities Exchange Act of 1934 by making misrepresentations and omissions of material fact about the Company's financial condition and operations. Among other things, the complaint alleges that the defendants engaged in a scheme and course of conduct to defraud or deceive purchasers of the common stock of AHP by omitted and/or misrepresenting material information concerning the company's weight-loss drugs Redux (dexfenfluramine hydrochloride) and Pondimin (fenfluramine hydrochloride) while insiders were selling millions of dollars worth of their stock in the company.